TRPX - Therapix Biosciences Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.4400
-0.1500 (-9.43%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.5900
Open1.6000
Bid0.0000 x 1800
Ask1.7600 x 4000
Day's Range1.4000 - 1.6250
52 Week Range1.4000 - 8.9500
Volume80,022
Avg. Volume59,170
Market Cap6.353M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.8200
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.00
  • Benzinga

    The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 7.) Collegium Pharmaceutical Inc (NASDAQ: COLL ...

  • Therapix Biosciences and Destiny Biosciences Global Corp. Mutually Decide to Discontinue Negotiations on Planned Merger
    PR Newswire

    Therapix Biosciences and Destiny Biosciences Global Corp. Mutually Decide to Discontinue Negotiations on Planned Merger

    TEL AVIV, Israel, Nov. 7, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, along with Destiny Biosciences Global Corp. ("Destiny"), announced today the mutual decision to discontinue negotiations on the previously announced proposed merger. On July 23, 2019, Therapix announced the signing of a Letter of Intent for a proposed merger with Destiny. According to the Letter of Intent, the parties agreed to allow until October 31, 2019 to complete definitive agreements before abandoning the transaction.

  • Top Marijuana Stocks on the NASDAQ
    Investopedia

    Top Marijuana Stocks on the NASDAQ

    The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges. Learn about the marijuana stocks on the Nasdaq.

  • Therapix Biosciences Announces Positive Data From Recent Pre-clinical Study for New Drug Candidate THX-210
    PR Newswire

    Therapix Biosciences Announces Positive Data From Recent Pre-clinical Study for New Drug Candidate THX-210

    TEL AVIV, Israel, Oct. 15, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today positive results in its pre-clinical study evaluating THX-210, a proprietary novel pharmaceutical preparation containing non-psychoactive cannabinoid cannabidiol (CBD) and palmitoylethanolamide (PEA). THX-210 is intended for the treatment of epilepsy, as well as inflammatory conditions. The study consisted of in vitro tests which examined potential synergy between CBD and PEA.

  • Benzinga

    The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout

    The following is a roundup of top developments in the biotech space over the last 24 hours.  Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 10.) The Medicines Company (NASDAQ: MDCO ) Ra ...

  • Therapix Biosciences Provides Update on Planned Merger With Destiny Biosciences Global Corp.
    PR Newswire

    Therapix Biosciences Provides Update on Planned Merger With Destiny Biosciences Global Corp.

    TEL AVIV, Israel, Oct. 10, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today an update on its planned merger with Destiny Biosciences Global Corp. ("Destiny"). On July 23, 2019, Therapix announced the signing of a Letter of Intent for a proposed merger with Destiny. If completed, the transaction will create a combined company that focuses on Therapix's proprietary IP and related technology, and assets pertaining to all clinical stage pharmaceutical applications and Destiny's genomics-based breeding techniques and development capabilities.

  • Nasdaq Grants Therapix Biosciences Extension to Comply With Stockholders' Equity Requirement
    PR Newswire

    Nasdaq Grants Therapix Biosciences Extension to Comply With Stockholders' Equity Requirement

    TEL AVIV, Israel, Aug. 27, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today that the Nasdaq Stock Market has granted the Company an extension until November 18, 2019, to regain compliance with Nasdaq Listing Rule 5550(b)(1), which will permit the continued listing of Therapix's stock on the Nasdaq Stock Market. As previously reported on May 23, 2019, Therapix received a letter notifying the Company that the stockholders' equity reported in the Company's Annual Report on Form 20-F for the year ended December 31, 2018, was below the minimum stockholders' equity of $2,500,000 required for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq listing rule 5550(b)(1).

  • Therapix Biosciences Announces Canadian Product License Issuance for TheraPEA (CannAmide™), a Non-Opiate Based Pain Management Supplement
    PR Newswire

    Therapix Biosciences Announces Canadian Product License Issuance for TheraPEA (CannAmide™), a Non-Opiate Based Pain Management Supplement

    This license is issued by Health Canada under the authority of the Natural Health Products Regulations. Dosage form of the described natural health product is tablets composed of 400mg PEA with a recommended dose of 1 tablet 3 times daily.

  • Benzinga

    Cannabis M&A: Therapix Biosciences, Destiny Biosciences Plan Stock-For-Stock Deal

    THERAPIX BIOSCI/S ADR (NASDAQ: TRPX ) said Tuesday that it has signed a letter of intent for a merger with the Canadian cannabis company Destiny Biosciences. The deal is a stock-for-stock transaction valuing ...

  • Therapix Biosciences Signs LOI to Merge With Destiny Biosciences Global Corp. in a Stock for Stock Transaction Valuing Therapix at US$48 Million
    PR Newswire

    Therapix Biosciences Signs LOI to Merge With Destiny Biosciences Global Corp. in a Stock for Stock Transaction Valuing Therapix at US$48 Million

    TEL AVIV, Israel, July 23, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or "the Company") (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today the signing of a letter of intent (the "LOI") for a proposed merger with Destiny Biosciences Global Corp. ("Destiny"). The transaction will create a combined company that focuses on Therapix's proprietary IP and related technology, and assets pertaining to all clinical stage pharmaceutical applications and Destiny's genomics-based breeding techniques and development capabilities.

  • Therapix Biosciences Announces First Quarter 2019 Condensed Financial Data
    PR Newswire

    Therapix Biosciences Announces First Quarter 2019 Condensed Financial Data

    TEL AVIV, Israel , July 5, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or "the Company") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on ...

  • Therapix Biosciences Announces Interim Results of Phase IIa Study at Assuta Medical Center for Obstructive Sleep Apnea Program
    PR Newswire

    Therapix Biosciences Announces Interim Results of Phase IIa Study at Assuta Medical Center for Obstructive Sleep Apnea Program

    TEL AVIV, Israel, June 18, 2019 /PRNewswire/  - Therapix Biosciences Ltd. ("Therapix" or "the Company") (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today interim results from its Phase IIa clinical study at Assuta Medical Center in Israel, suggesting that THX-110, a combination of dronabinol (∆-9-tetrahydracannabinol) and CannAmide™ (palmitoylethanolamide, or PEA), positively affects symptoms in adult subjects with obstructive sleep apnea (OSA). The study is being conducted under the leadership of Professor Yaron Dagan, head of the Sleep Medicine Institute at Assuta, and Principal Investigator, Dr. Lilach Kemer.

  • Therapix Biosciences Issues Shareholder Update Letter
    PR Newswire

    Therapix Biosciences Issues Shareholder Update Letter

    TEL AVIV, Israel, May 29, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today released a shareholder update letter from its Chairman and CEO, Dr. Ascher Shmulewitz. On Friday, May 24, 2019, the closing price of Therapix Biosciences' ADRs dropped 24% from the prior day's closing price. The drop followed our announcement that the Company received a notification from Nasdaq regarding non-compliance with Nasdaq's minimum stockholders' equity standard, and other challenging events, including our failed investment in the pain clinics in Tennessee, and the collapse of the planned acquisition of the Company by FSD Pharma Inc. in December 2018.

  • Benzinga

    The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs May 23.) ArQule, Inc. (NASDAQ: ARQL ) Turning Point ...

  • Therapix Biosciences Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Non-Compliance
    PR Newswire

    Therapix Biosciences Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Non-Compliance

    TEL AVIV, Israel , May 23, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. (" Therapix " or the " Company ") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing ...

  • Therapix Biosciences Announces Pricing of $2.25 Million Registered Direct Offering
    PR Newswire

    Therapix Biosciences Announces Pricing of $2.25 Million Registered Direct Offering

    TEL AVIV, Israel, March 28, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced that it has entered into definitive agreements with several accredited and institutional investors providing for the issuance of an aggregate of 642,853 American depositary shares (ADS) at a purchase price of $3.50 per ADS in a registered direct offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

  • Therapix Biosciences Appoints Ambassador Ron Prosor as Executive Advisor
    PR Newswire

    Therapix Biosciences Appoints Ambassador Ron Prosor as Executive Advisor

    TEL AVIV, Israel, March 19, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today that the Company has appointed Ambassador Ron Prosor as a global growth strategy and international business development advisor. Ambassador Prosor, a seasoned Diplomat for the Israeli Ministry of Foreign Affairs and Israel's former Permanent Representative to the United Nations, will support Therapix to develop and execute its global growth strategy and international business development.

  • Market Exclusive

    Cannabis Stock News Weekend Roundup December 23

    Cannabis News On Dec. 20, President Trump signed the Agriculture Improvement Act of 2018 into law, legalizing hemp in the U.S. Among other things, this new law changes certain federal authorities relating to the production and marketing of hemp, defined as cannabis (Cannabis sativa L.), and derivatives of cannabis with extremely low (less than 0.3% […] The post Cannabis Stock News Weekend Roundup December 23 appeared first on Market Exclusive.

  • Therapix Biosciences Terminates FSD Acquisition Letter of Intent
    PR Newswire

    Therapix Biosciences Terminates FSD Acquisition Letter of Intent

    TEL AVIV, Israel , Dec. 21, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (" Therapix " or the " Company ") (NASDAQ: TRPX), a specialty, clinical-stage pharmaceutical company focusing ...

  • Therapix Biosciences Provides Update Regarding FSD Acquisition
    PR Newswire

    Therapix Biosciences Provides Update Regarding FSD Acquisition

    TEL AVIV, Israel, Dec. 11, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, is providing an update to shareholders regarding the previously announced binding letter of intent dated October 22, 2018 (the "LOI") with FSD Pharma Inc. ("FSD") (CSE:HUGE) (FSDDF) (0K9.F) for the acquisition of the Company by FSD (the "Transaction").

  • Therapix Biosciences Reports Third Quarter 2018 Financial Results and Provides Business Update
    PR Newswire

    Therapix Biosciences Reports Third Quarter 2018 Financial Results and Provides Business Update

    TEL AVIV, Israel , Dec. 3, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company" or "Therapix"), a specialty, clinical-stage pharmaceutical company focusing on ...

  • Therapix Biosciences Clarifies Terms of Recently Issued Convertible Debenture
    PR Newswire

    Therapix Biosciences Clarifies Terms of Recently Issued Convertible Debenture

    TEL AVIV, Israel, Nov. 29, 2018 /PRNewsire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced on November 27, 2018 that the Company has entered into a securities purchase agreement with YA II PN Ltd., a fund managed by Yorkville Advisors Global, for the sale in a private placement of up to $2.5 million in principal amount of unsecured convertible debentures (the "Debentures").

  • Therapix Biosciences Issues $1,500,000 Convertible Debenture
    PR Newswire

    Therapix Biosciences Issues $1,500,000 Convertible Debenture

    TEL AVIV, Israel , Nov. 27, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (" Therapix " or the " Company ") (NASDAQ: TRPX) a specialty, clinical-stage pharmaceutical company focusing ...